Research News

Solid tumors are not merely collections of malignant cells but complex ecosystems comprising tumor cells, stromal cells, and the extracellular matrix (ECM). The tumor microenvironment (TME) fosters immunosuppression through tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and cancer-associated fibroblasts (CAFs), while physical barriers such as dense ECM and abnormal vasculature hinder drug penetration

A team from Flinders University’s Biomedical Nanoengineering Laboratory has found that vanillin has pronounced antioxidant, anti-inflammatory and antibacterial properties, making it a good candidate for wound-healing formulations.

A major prospective clinical trial has identified clinical and molecular characteristics that may help determine which patients with early-stage HER2-positive breast cancer are most likely to achieve a pathologic complete response (pCR) after a shorter, less intensive chemotherapy regimen.

A cancer drug currently being evaluated in clinical trials may work through a different biological mechanism than scientists originally believed, according to a new study led by the University of Sydney in collaboration with Goethe University, the University of Oxford and the Institute of Cancer Research, London.

MSD announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS).

Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes.

Novo Nordisk today announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg.

An international team of researchers has identified a previously unrecognized inherited retinal disorder linked to a rare variant in the EFEMP1 gene. The newly characterized condition primarily affects the peripheral retina and rod photoreceptors involved in vision under low-light conditions, while central vision can remain relatively preserved for many years.